Clinical Trial Update: Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 efficacy and safety study of ABT-288 in mild-to-moderate Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ABT-288 (ABT-288)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED